OBJECTIVE: Joint pain is the major clinical symptom of arthritis that affects millions of people. Controlling the excitability of knee-innervating dorsal root ganglion (DRG) neurons (knee neurons) could potentially provide pain relief. We undertook this study to evaluate whether the newly engineered adeno-associated virus (AAV) serotype, AAV-PHP.S, can deliver functional artificial receptors to control knee neuron excitability following intraarticular knee injection. METHODS: The AAV-PHP.S virus, packaged with dTomato fluorescent protein and either excitatory (Gq ) or inhibitory (Gi ) designer receptors exclusively activated by designer drugs (DREADDs), was injected into the knee joints of adult mice. Labeling of DRG neurons with AAV-PHP.S from the knee was evaluated using immunohistochemistry. The functionality of Gq - and Gi -DREADDs was evaluated using whole-cell patch clamp electrophysiology on acutely cultured DRG neurons. Pain behavior in mice was assessed using a digging assay, dynamic weight bearing, and rotarod performance, before and after intraperitoneal administration of the DREADD activator, Compound 21. RESULTS: We showed that AAV-PHP.S can deliver functional genes into ~7% of lumbar DRG neurons when injected into the knee joint in a similar manner to the well-established retrograde tracer, fast blue. Short-term activation of AAV-PHP.S-delivered Gq -DREADD increased excitability of knee neurons in vitro (P = 0.02 by unpaired t-test), without inducing overt pain in mice when activated in vivo. By contrast, in vivo Gi -DREADD activation alleviated digging deficits induced by Freund's complete adjuvant-mediated knee inflammation (P = 0.0002 by repeated-measures analysis of variance [ANOVA] followed by Holm-Sidak multiple comparisons test). A concomitant decrease in knee neuron excitability was observed in vitro (P = 0.005 by ANOVA followed by Holm-Sidak multiple comparisons test). CONCLUSION: We describe an AAV-mediated chemogenetic approach to specifically control joint pain, which may be utilized in translational arthritic pain research.
OBJECTIVE: Joint pain is the major clinical symptom of arthritis that affects millions of people. Controlling the excitability of knee-innervating dorsal root ganglion (DRG) neurons (knee neurons) could potentially provide pain relief. We undertook this study to evaluate whether the newly engineered adeno-associated virus (AAV) serotype, AAV-PHP.S, can deliver functional artificial receptors to control knee neuron excitability following intraarticular knee injection. METHODS: The AAV-PHP.S virus, packaged with dTomato fluorescent protein and either excitatory (Gq ) or inhibitory (Gi ) designer receptors exclusively activated by designer drugs (DREADDs), was injected into the knee joints of adult mice. Labeling of DRG neurons with AAV-PHP.S from the knee was evaluated using immunohistochemistry. The functionality of Gq - and Gi -DREADDs was evaluated using whole-cell patch clamp electrophysiology on acutely cultured DRG neurons. Pain behavior in mice was assessed using a digging assay, dynamic weight bearing, and rotarod performance, before and after intraperitoneal administration of the DREADD activator, Compound 21. RESULTS: We showed that AAV-PHP.S can deliver functional genes into ~7% of lumbar DRG neurons when injected into the knee joint in a similar manner to the well-established retrograde tracer, fast blue. Short-term activation of AAV-PHP.S-delivered Gq -DREADD increased excitability of knee neurons in vitro (P = 0.02 by unpaired t-test), without inducing overt pain in mice when activated in vivo. By contrast, in vivo Gi -DREADD activation alleviated digging deficits induced by Freund's complete adjuvant-mediated knee inflammation (P = 0.0002 by repeated-measures analysis of variance [ANOVA] followed by Holm-Sidak multiple comparisons test). A concomitant decrease in knee neuron excitability was observed in vitro (P = 0.005 by ANOVA followed by Holm-Sidak multiple comparisons test). CONCLUSION: We describe an AAV-mediated chemogenetic approach to specifically control joint pain, which may be utilized in translational arthritic pain research.
Authors: M Jimenez-Gonzalez; R Li; L E Pomeranz; A Alvarsson; R Marongiu; R F Hampton; M G Kaplitt; R C Vasavada; G J Schwartz; S A Stanley Journal: Nat Biomed Eng Date: 2022-07-14 Impact factor: 29.234
Authors: Xinhong Chen; Sripriya Ravindra Kumar; Cameron D Adams; Daping Yang; Tongtong Wang; Damien A Wolfe; Cynthia M Arokiaraj; Victoria Ngo; Lillian J Campos; Jessica A Griffiths; Takako Ichiki; Sarkis K Mazmanian; Peregrine B Osborne; Janet R Keast; Cory T Miller; Andrew S Fox; Isaac M Chiu; Viviana Gradinaru Journal: Neuron Date: 2022-05-27 Impact factor: 18.688
Authors: A Kagiava; J Richter; C Tryfonos; M Leal-Julià; I Sargiannidou; C Christodoulou; A Bosch; K A Kleopa Journal: Sci Rep Date: 2021-12-02 Impact factor: 4.379
Authors: Md Anik Ashfaq Khan; Klaus Schoene; John Cashman; Ahmed Abd El Wahed; Uwe Truyen Journal: J Virol Methods Date: 2022-10-06 Impact factor: 2.623
Authors: Michael C Lee; Michael S Nahorski; James R F Hockley; Van B Lu; Gillian Ison; Luke A Pattison; Gerard Callejo; Kaitlin Stouffer; Emily Fletcher; Christopher Brown; Ichrak Drissi; Daniel Wheeler; Patrik Ernfors; David Menon; Frank Reimann; Ewan St John Smith; C Geoffrey Woods Journal: Cell Rep Date: 2020-07-21 Impact factor: 9.423